293 related articles for article (PubMed ID: 34060205)
21. Discovery of the antitumor activities of a potent DCN1 inhibitor compound 383 targeting LSD1 in gastric cancer.
Song Z; Gao K; Asmamaw MD; Liu YJ; Zheng YC; Shi XJ; Liu HM
Eur J Pharmacol; 2022 Feb; 916():174725. PubMed ID: 34953802
[TBL] [Abstract][Full Text] [Related]
22. Knocking down LSD1 inhibits the stemness features of colorectal cancer stem cells.
Chen J; Zhao J; Ding J; Wang Z; Du J; Wu C
Braz J Med Biol Res; 2020; 53(7):e9230. PubMed ID: 32520208
[TBL] [Abstract][Full Text] [Related]
23. Lysine-specific demethylase 1-mediated demethylation of histone H3 lysine 9 contributes to interleukin 1β-induced microsomal prostaglandin E synthase 1 expression in human osteoarthritic chondrocytes.
El Mansouri FE; Nebbaki SS; Kapoor M; Afif H; Martel-Pelletier J; Pelletier JP; Benderdour M; Fahmi H
Arthritis Res Ther; 2014 May; 16(3):R113. PubMed ID: 24886859
[TBL] [Abstract][Full Text] [Related]
24. The Role of Lysine-Specific Demethylase 1 (LSD1) in Shaping the Endothelial Inflammatory Response.
Wojtala M; Rybaczek D; Wielgus E; Sobalska-Kwapis M; Strapagiel D; Balcerczyk A
Cell Physiol Biochem; 2021 Oct; 55(5):569-589. PubMed ID: 34612026
[TBL] [Abstract][Full Text] [Related]
25. Demethylase-independent roles of LSD1 in regulating enhancers and cell fate transition.
Zeng C; Chen J; Cooke EW; Subuddhi A; Roodman ET; Chen FX; Cao K
Nat Commun; 2023 Aug; 14(1):4944. PubMed ID: 37607921
[TBL] [Abstract][Full Text] [Related]
26. Loss of LSD1 (lysine-specific demethylase 1) suppresses growth and alters gene expression of human colon cancer cells in a p53- and DNMT1(DNA methyltransferase 1)-independent manner.
Jin L; Hanigan CL; Wu Y; Wang W; Park BH; Woster PM; Casero RA
Biochem J; 2013 Jan; 449(2):459-68. PubMed ID: 23072722
[TBL] [Abstract][Full Text] [Related]
27. LSD1 promotes prostate cancer reprogramming by repressing TP53 signaling independently of its demethylase function.
Kumaraswamy A; Duan Z; Flores D; Zhang C; Sehrawat A; Hu YM; Swaim OA; Rodansky E; Storck WK; Kuleape JA; Bedi K; Mannan R; Wang XM; Udager A; Ravikumar V; Bankhead A; Coleman I; Lee JK; Morrissey C; Nelson PS; Chinnaiyan AM; Rao A; Xia Z; Yates JA; Alumkal JJ
JCI Insight; 2023 Aug; 8(15):. PubMed ID: 37440313
[TBL] [Abstract][Full Text] [Related]
28. Lysine-specific demethylase-1 regulates fibroblast activation in pulmonary fibrosis via TGF-β1/Smad3 pathway.
Pan X; Li J; Tu X; Wu C; Liu H; Luo Y; Dong X; Li X; Pan LL; Sun J
Pharmacol Res; 2020 Feb; 152():104592. PubMed ID: 31830521
[TBL] [Abstract][Full Text] [Related]
29. Upregulation of the long noncoding RNA FOXD2-AS1 promotes carcinogenesis by epigenetically silencing EphB3 through EZH2 and LSD1, and predicts poor prognosis in gastric cancer.
Xu TP; Wang WY; Ma P; Shuai Y; Zhao K; Wang YF; Li W; Xia R; Chen WM; Zhang EB; Shu YQ
Oncogene; 2018 Sep; 37(36):5020-5036. PubMed ID: 29789713
[TBL] [Abstract][Full Text] [Related]
30. Lysine-specific demethylase 1 activation by vitamin B2 attenuates efficacy of apatinib for proliferation and migration of gastric cancer cell MGC-803.
Ma JL; Zhang T; Suo FZ; Chang J; Wan XB; Feng XJ; Zheng YC; Liu HM
J Cell Biochem; 2018 Jun; 119(6):4957-4966. PubMed ID: 29384217
[TBL] [Abstract][Full Text] [Related]
31. Crosstalk between lysine-specific demethylase 1 (LSD1) and histone deacetylases mediates antineoplastic efficacy of HDAC inhibitors in human breast cancer cells.
Vasilatos SN; Katz TA; Oesterreich S; Wan Y; Davidson NE; Huang Y
Carcinogenesis; 2013 Jun; 34(6):1196-207. PubMed ID: 23354309
[TBL] [Abstract][Full Text] [Related]
32. CBB1003, a lysine-specific demethylase 1 inhibitor, suppresses colorectal cancer cells growth through down-regulation of leucine-rich repeat-containing G-protein-coupled receptor 5 expression.
Hsu HC; Liu YS; Tseng KC; Yang TS; Yeh CY; You JF; Hung HY; Chen SJ; Chen HC
J Cancer Res Clin Oncol; 2015 Jan; 141(1):11-21. PubMed ID: 25060070
[TBL] [Abstract][Full Text] [Related]
33. Discovery of acridine-based LSD1 inhibitors as immune activators targeting LSD1 in gastric cancer.
Liu HM; Xiong XP; Wu JW; Chen HX; Zhou Y; Ji SK; Dai XJ; Zheng YC; Liu HM
Eur J Med Chem; 2023 May; 251():115255. PubMed ID: 36913900
[TBL] [Abstract][Full Text] [Related]
34. Lysine-Specific Histone Demethylase 1 Promotes Oncogenesis of the Esophageal Squamous Cell Carcinoma by Upregulating DUSP4.
Han J; Ye S; Chen J; Wang K; Jin J; Zeng Z; Xue S
Biochemistry (Mosc); 2021 Dec; 86(12):1624-1634. PubMed ID: 34937541
[TBL] [Abstract][Full Text] [Related]
35. LSD1 activates a lethal prostate cancer gene network independently of its demethylase function.
Sehrawat A; Gao L; Wang Y; Bankhead A; McWeeney SK; King CJ; Schwartzman J; Urrutia J; Bisson WH; Coleman DJ; Joshi SK; Kim DH; Sampson DA; Weinmann S; Kallakury BVS; Berry DL; Haque R; Van Den Eeden SK; Sharma S; Bearss J; Beer TM; Thomas GV; Heiser LM; Alumkal JJ
Proc Natl Acad Sci U S A; 2018 May; 115(18):E4179-E4188. PubMed ID: 29581250
[TBL] [Abstract][Full Text] [Related]
36. A comprehensive review of lysine-specific demethylase 1 and its roles in cancer.
Hosseini A; Minucci S
Epigenomics; 2017 Aug; 9(8):1123-1142. PubMed ID: 28699367
[TBL] [Abstract][Full Text] [Related]
37. Lysine-Specific Demethylase 1 (LSD1) epigenetically controls osteoblast differentiation.
Rummukainen P; Tarkkonen K; Dudakovic A; Al-Majidi R; Nieminen-Pihala V; Valensisi C; Hawkins RD; van Wijnen AJ; Kiviranta R
PLoS One; 2022; 17(3):e0265027. PubMed ID: 35255108
[TBL] [Abstract][Full Text] [Related]
38. Lactadherin immunoblockade in small extracellular vesicles inhibits sEV-mediated increase of pro-metastatic capacities.
Durán-Jara E; Del Campo M; Gutiérrez V; Wichmann I; Trigo C; Ezquer M; Lobos-González L
Biol Res; 2024 Jan; 57(1):1. PubMed ID: 38173019
[TBL] [Abstract][Full Text] [Related]
39. Expression, Purification, and Biochemical Analysis of the LSD1/KDM1A Histone Demethylase.
Laurent B; Shi Y
Methods Enzymol; 2016; 573():241-59. PubMed ID: 27372756
[TBL] [Abstract][Full Text] [Related]
40. Overexpression of lysine-specific demethylase 1 promotes androgen-independent transition of human prostate cancer LNCaP cells through activation of the AR signaling pathway and suppression of the p53 signaling pathway.
Li X; Li T; Chen D; Zhang P; Song Y; Zhu H; Xiao Y; Xing Y
Oncol Rep; 2016 Jan; 35(1):584-92. PubMed ID: 26534764
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
